BRPI0210707B8 - composição de solução para administração tópica no tratamento de distúrbios alérgicos ou inflamatórios do olho e do nariz e seu método de preparação - Google Patents

composição de solução para administração tópica no tratamento de distúrbios alérgicos ou inflamatórios do olho e do nariz e seu método de preparação

Info

Publication number
BRPI0210707B8
BRPI0210707B8 BRPI0210707A BR0210707A BRPI0210707B8 BR PI0210707 B8 BRPI0210707 B8 BR PI0210707B8 BR PI0210707 A BRPI0210707 A BR PI0210707A BR 0210707 A BR0210707 A BR 0210707A BR PI0210707 B8 BRPI0210707 B8 BR PI0210707B8
Authority
BR
Brazil
Prior art keywords
nose
eye
inflammatory disorders
topical administration
allergic
Prior art date
Application number
BRPI0210707A
Other languages
English (en)
Portuguese (pt)
Other versions
BR0210707A (pt
BRPI0210707B1 (pt
Inventor
J Castillo Ernesto
G Bhagat Haresh
Zhang Huixiang
Paul Bullock Joseph
N Singh Onkar
C Dixit Suresh
Wehsin Han Wesley
Original Assignee
Alcon Pharmaceuticals Ltd
Alcon Inc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23162841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0210707(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Pharmaceuticals Ltd, Alcon Inc, Novartis Ag filed Critical Alcon Pharmaceuticals Ltd
Publication of BR0210707A publication Critical patent/BR0210707A/pt
Publication of BRPI0210707B1 publication Critical patent/BRPI0210707B1/pt
Publication of BRPI0210707B8 publication Critical patent/BRPI0210707B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0210707A 2001-06-27 2002-06-19 composição de solução para administração tópica no tratamento de distúrbios alérgicos ou inflamatórios do olho e do nariz e seu método de preparação BRPI0210707B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30131501P 2001-06-27 2001-06-27
PCT/US2002/019417 WO2003002093A1 (en) 2001-06-27 2002-06-19 Olopatadine formulations for topical administration

Publications (3)

Publication Number Publication Date
BR0210707A BR0210707A (pt) 2004-07-20
BRPI0210707B1 BRPI0210707B1 (pt) 2015-08-04
BRPI0210707B8 true BRPI0210707B8 (pt) 2021-05-25

Family

ID=23162841

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0210707A BRPI0210707B8 (pt) 2001-06-27 2002-06-19 composição de solução para administração tópica no tratamento de distúrbios alérgicos ou inflamatórios do olho e do nariz e seu método de preparação

Country Status (20)

Country Link
US (2) US6995186B2 (enExample)
EP (1) EP1399127B1 (enExample)
JP (5) JP4827374B2 (enExample)
KR (1) KR100884711B1 (enExample)
CN (1) CN1211125C (enExample)
AR (1) AR034619A1 (enExample)
AT (1) ATE295149T1 (enExample)
AU (1) AU2002310461B2 (enExample)
BR (1) BRPI0210707B8 (enExample)
CA (1) CA2447924C (enExample)
DE (1) DE60204142T2 (enExample)
DK (1) DK1399127T3 (enExample)
ES (1) ES2238574T3 (enExample)
GC (1) GC0000397A (enExample)
MX (1) MXPA03011947A (enExample)
PL (1) PL205565B1 (enExample)
PT (1) PT1399127E (enExample)
TW (1) TWI231759B (enExample)
WO (1) WO2003002093A1 (enExample)
ZA (1) ZA200308771B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055152A1 (en) * 2008-08-26 2010-03-04 Trutek Corporation Antihistamine and antihistamine-like nasal application, products, and method
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
US20050209312A1 (en) * 2004-03-19 2005-09-22 Bausch & Lomb Incorporated Carboxylic acid derivatives of doxepin formulations preserved with low-irritation preservative
CN1942173B (zh) * 2004-04-08 2012-05-09 协和发酵麒麟株式会社 稳定性提高的固体制剂及其制造方法
US20070225356A1 (en) * 2004-04-21 2007-09-27 Kyowa Hakko Kogo Co., Ltd Preventive and/or Therapeutic Agent for Chronic Sinusitis
AU2005259911A1 (en) * 2004-06-28 2006-01-12 Alcon, Inc. Topical formulations for treating allergic diseases
AU2005309951B2 (en) * 2004-11-24 2011-07-07 Alcon, Inc. Method of delivering nasal spray
WO2006097458A1 (en) * 2005-03-15 2006-09-21 Nycomed Gmbh Novel combination
EP1901708B1 (en) 2005-07-08 2013-09-11 Senju Pharmaceutical Co., Ltd. Percutaneously absorptive ophthalmic preparation comprising olopatadine
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
US20080114076A1 (en) * 2006-11-09 2008-05-15 Alcon Manufacturing Ltd. Punctal plug comprising a water-insoluble polymeric matrix
ZA200902587B (en) 2006-11-09 2010-06-30 Alcon Res Ltd Water insoluble polymer matrix for drug delivery
JP5323720B2 (ja) * 2006-12-18 2013-10-23 アルコン リサーチ， リミテッド 眼用薬物送達のためのデバイスおよび方法
WO2008093358A2 (en) * 2007-01-29 2008-08-07 Sun Pharmaceutical Industries Limited Aqueous topical solution containing olopatadine
HUE026162T2 (en) * 2007-02-07 2016-05-30 Novartis Ag Olopatadine preparation for topical nasal administration
WO2008120249A1 (en) * 2007-03-30 2008-10-09 Sifi S.P.A. Pharmaceutical formulations based on apolar and polar lipids for ophthalmic use
US20080254029A1 (en) * 2007-04-11 2008-10-16 Alcon Research, Ltd. Use of an Inhibitor of TNFa Plus an Antihistamine to Treat Allergic Rhinitis and Allergic Conjunctivitis
US20100227917A1 (en) * 2007-09-06 2010-09-09 Masashi Nakakura EYE DROP CONTAINING DIBENZ[b,e]OXEPIN DERIVATIVE
WO2009142950A1 (en) * 2008-05-19 2009-11-26 Alcon Research, Ltd. Pharmaceutical compositions having carboxyvinyl polymer and povidone polymer
CN102089039B (zh) * 2008-08-26 2013-10-23 博磊科技股份有限公司 带静电荷口罩过滤产品和用于增加过滤效率的方法
JP2012509250A (ja) * 2008-08-28 2012-04-19 トルテック コーポレーション 抗ヒスタミン及び抗ヒスタミン様経鼻適用製品及び方法
US9458198B1 (en) 2009-06-26 2016-10-04 Shire Orphan Therapies Gmbh Cyclic peptide-based NPR-B agonists
PT2453872E (pt) * 2009-07-17 2013-10-30 Alcon Res Ltd Regime de pulverização nasal de olopatadina para crianças
WO2011027322A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Extended release dosage form containing olopatadine for oral administration
US8551938B2 (en) * 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
UY32902A (es) 2009-09-25 2011-02-28 Alcon Res Ltd Nuevos agonistas de npr-b
CN102548536A (zh) * 2009-10-01 2012-07-04 爱尔康研究有限公司 奥洛他定组合物及其用途
AR078446A1 (es) 2009-12-18 2011-11-09 Alcon Res Ltd Agonistas de npr-b. uso.
WO2011075471A2 (en) 2009-12-18 2011-06-23 Alcon Research, Ltd. Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders
CN103140215A (zh) * 2010-07-21 2013-06-05 爱尔康研究有限公司 具有提高的溶解度特征的药物组合物
WO2012063237A2 (en) * 2010-11-08 2012-05-18 Healor Ltd. Buffered ophthalmic compositions and methods of use thereof
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
CN102885767A (zh) * 2012-11-02 2013-01-23 江苏吉贝尔药业有限公司 一种新的盐酸奥洛他定滴眼液及其制备方法
WO2018144742A1 (en) 2017-02-01 2018-08-09 Shire Human Genetic Therapies, Inc. Compounds and compositions for the treatment of ophthalmic disorders
WO2018235935A1 (ja) * 2017-06-23 2018-12-27 参天製薬株式会社 水溶性粘稠化剤を含有する医薬組成物
JP7037349B2 (ja) * 2017-06-23 2022-03-16 参天製薬株式会社 水溶性粘稠化剤を含有する医薬組成物
CN114980881A (zh) * 2019-12-06 2022-08-30 东兴药品工业株式会社 包含奥洛他定的鼻用组合物
KR102705675B1 (ko) * 2020-03-31 2024-09-11 산텐 세이야꾸 가부시키가이샤 수지제 용기에 충전된 은염 함유 안과용 수성 조성물
CN111700860A (zh) * 2020-07-09 2020-09-25 浙江尖峰药业有限公司 盐酸奥洛他定滴眼液及其制备方法
CN119318630B (zh) * 2024-10-16 2025-08-22 苏州欧康维视生物科技有限公司 一种阿托品药物组合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4370324A (en) 1980-09-17 1983-01-25 Bernstein Joel E Method and composition for treating and preventing irritation of the eyes
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4749700A (en) 1984-10-23 1988-06-07 Nastech Pharmaceutical Co, Inc. Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
JPS6310784A (ja) 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤
DE3877904D1 (de) 1987-11-13 1993-03-11 Asta Pharma Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
IT1250691B (it) 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
JP3662944B2 (ja) 1993-08-24 2005-06-22 協和醗酵工業株式会社 点鼻剤
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US5641805A (en) 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
US6207684B1 (en) 1997-06-09 2001-03-27 Bridge Pharma, Inc. Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use
CN1114401C (zh) 1998-07-14 2003-07-16 阿尔康实验室公司 11－(3－二甲氨基亚丙基)－6,11－二氢二苯并[b,e]噁庚英－2－乙酸用于制药的新用途
CA2340225A1 (en) * 1998-10-27 2000-05-04 Wesley Wehsin Han Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap
US6146622A (en) * 1998-10-27 2000-11-14 Alcon Laboratories, Inc. Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
US6274626B1 (en) * 1998-12-22 2001-08-14 Bausch & Lomb Incorporated Pheniramine-containing compositions and method for treating allergic responses
US6174914B1 (en) 1999-06-15 2001-01-16 Alcon Laboratories, Inc. Method of inhibiting cytokine release from human ocular cells
BR0014117A (pt) 1999-09-21 2002-05-14 Alcon Lab Inc Uso de sabÈes de acido graxo/aminoácido para aumentar a eficácia antimicrobiana de composições farmacêutica tópicas
CN1376066A (zh) 1999-11-18 2002-10-23 爱尔康公司 H1拮抗剂和安全类固醇的治疗眼病的用途
PT1250133E (pt) * 2000-01-25 2005-05-31 Alcon Inc Composicoes antialergicas oftalmicas adequadas a utilizacao com lentes de contacto
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
CN1297275C (zh) 2002-11-12 2007-01-31 爱尔康公司 抗过敏剂和类固醇用于治疗过敏性鼻炎的用途

Also Published As

Publication number Publication date
WO2003002093A1 (en) 2003-01-09
KR20040025919A (ko) 2004-03-26
US6995186B2 (en) 2006-02-07
US20030055102A1 (en) 2003-03-20
US7402609B2 (en) 2008-07-22
CN1525849A (zh) 2004-09-01
CN1211125C (zh) 2005-07-20
TWI231759B (en) 2005-05-01
ATE295149T1 (de) 2005-05-15
PL205565B1 (pl) 2010-05-31
AU2002310461B2 (en) 2006-05-18
PL367780A1 (en) 2005-03-07
JP2012107046A (ja) 2012-06-07
KR100884711B1 (ko) 2009-02-19
GC0000397A (en) 2007-03-31
ZA200308771B (en) 2005-01-26
DE60204142T2 (de) 2005-10-06
AR034619A1 (es) 2004-03-03
JP2009114213A (ja) 2009-05-28
EP1399127B1 (en) 2005-05-11
BR0210707A (pt) 2004-07-20
CA2447924C (en) 2009-11-03
HK1059573A1 (en) 2004-07-09
JP4827374B2 (ja) 2011-11-30
JP2004536096A (ja) 2004-12-02
ES2238574T3 (es) 2005-09-01
US20050158387A1 (en) 2005-07-21
CA2447924A1 (en) 2003-01-09
EP1399127A1 (en) 2004-03-24
PT1399127E (pt) 2005-07-29
DE60204142D1 (de) 2005-06-16
DK1399127T3 (da) 2005-06-13
MXPA03011947A (es) 2004-03-26
JP5328947B2 (ja) 2013-10-30
JP2013127005A (ja) 2013-06-27
BRPI0210707B1 (pt) 2015-08-04
JP2010150292A (ja) 2010-07-08

Similar Documents

Publication Publication Date Title
BRPI0210707B8 (pt) composição de solução para administração tópica no tratamento de distúrbios alérgicos ou inflamatórios do olho e do nariz e seu método de preparação
ES2998817T3 (en) Topical formulations comprising cannabidiol, method of preparing the composition and use thereof
ES2052784T3 (es) Procedimiento para la produccion de una composicion terapeutica administrable localmente para una enfermedad inflamatoria.
ES2949139T3 (es) Composición que elimina la congestión nasal y que tiene actividad antivírica
CY1120977T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
NO20044699L (no) Vaginalpleiesammensetning
KR101820184B1 (ko) 방부제가 없는 비마토프로스트 및 티몰롤 용액
BRPI0111591B8 (pt) composto, composição farmacêutica, e, usos de um composto
DOP2000000114A (es) Oxazolidinonas substituidas y su uso
EA200800056A1 (ru) Каннабиноидный активный фармацевтический ингредиент для лекарственных форм
BR0113861A (pt) Derivados de ácidos 3-(heteroaril acetamido)-2-oxo-azetidina-1-sulfÈnicos como agentes antibacterianos
BR0011799A (pt) Combinação de bactéria de ácido láctico e seu uso para a prevenção e/ou tratamento de infecções e condições inflamatórias
BR0207694A (pt) Composto ou um sal, solvato ou derivado fisiologicamente funcional deste, método para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, formulação farmacêutica, combinação, uso de um composto ou de um sal, solvato ou derivado fisiologicamente funcional deste farmaceuticamente aceitáveis, processo para a preparação de um composto ou de um sal, solvato ou derivado fisiologicamente funcional deste, e, intermediários
RU2011101713A (ru) Фармацевтическая композиция
BRPI0416854B8 (pt) suspensão aquosa estéril de ciclesonida adequada para nebulização, método para sua preparação e uso da dita suspensão, bem como produto farmacêutico
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
JP2003206241A (ja) 眼科用剤
BRPI0409818A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
BRPI0721255B8 (pt) composições de olopatadina para administração nasal tópica
BRPI0412131A (pt) métodos de tratamento de distúrbios oftálmicos, para evitar hemorragia retìnica, perda de acuidade visual, reduzir exsudatos duros e retardar progressão de dano retìnico
BR0317289A (pt) Método para tratar distúrbios do movimento usando derivados do ácido barbitúrico
RU2018125252A (ru) Синергическая комбинация пирролидонкарбоновой кислоты и/или ее солей и гиалуроновой кислоты и/или ее солей для применения в лечении и/или профилактике сухости и раздражения слизистых оболочек, и связанные фармацевтические композиции
BRPI0410246A (pt) composto, processo para a preparação de um composto, uso de um composto, método para o tratamento do corpo humano ou de animal não humano para combater infecção microbiana, e, composição farmacêutica
CA2901208A1 (en) Topical ocular analgesic agents

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/08/2015, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B25A Requested transfer of rights approved
B25A Requested transfer of rights approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/06/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2727 DE 11-04-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.